Patent intelligence · WO
WO 2025172541
NOUVELLE COMPOSITION POUR L'AMÉLIORATION DE LA RECONSTITUTION DE LA MOELLE OSSEUSE ET DE LA RÉCUPÉRATION PÉRIPHÉRIQUE DES NUMÉRATIONS DE NEUTROPHILES ET DE PLAQUETTES
NOUVELLE COMPOSITION POUR L'AMÉLIORATION DE LA RECONSTITUTION DE LA MOELLE OSSEUSE ET DE LA RÉCUPÉRATION PÉRIPHÉRIQUE DES NUMÉRATIONS DE NEU…
Patent details — WO 2025172541
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Aug 21, 2025
- Expiration
- Aug 16, 2045
- Applicant
- AOP ORPHAN PHARMACEUTICALS GMBH [AT]
- CPC classes
- A61K 31/ 137 A I, A61K 31/ 352 A I, A61K 31/ 402 A I, A61K 31/ 5575 A I
Quick answer
WO 2025172541 (NOUVELLE COMPOSITION POUR L'AMÉLIORATION DE LA RECONSTITUTION DE LA MOELLE OSSEUSE ET DE LA RÉCUPÉRATION PÉRIPHÉRIQUE DES NUMÉRATIONS DE NEUTROPHILES ET DE PLAQUETTES) is held by AOP ORPHAN PHARMACEUTICALS GMBH [AT]. Status: granted. Granted Aug 21, 2025. Expires Aug 16, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AOP ORPHAN PHARMACEUTICALS GMBH [AT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 137 A I, A61K 31/ 352 A I, A61K 31/ 402 A I, A61K 31/ 5575 A I, A61K 31/ 5578 A I, A61K 31/ 5585 A I
More from AOP ORPHAN PHARMACEUTICALS GMBH [AT]
Related pharmaceutical patents in our USPTO index.
-
WO 2025153663
LANDIOLOL COMPLEXÉ ENCAPSULÉ OU DISSOUS DANS UNE MATRICE LIPOPHILE
granted -
LT 3544598
CANNABINOIDS FOR PROPHYLACTIC TREATMENT OF INVOLUNTARY WEIGHT LOSS
granted -
EP 2988750
VERWENDUNG VON LANDIOLOLHYDROCHLORID BEI DER LANGZEITBEHANDLUNG VON TACHYARRHYTHMIEN
granted -
AU 2013258031
Parenteral esmolol formulation
granted -
AU 2009324043
Novel composition for treatment of essential thrombocythemia
granted -
AU 2008340179
Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
granted
Frequently asked questions
What is US patent 2025172541?
WO 2025172541 (NOUVELLE COMPOSITION POUR L'AMÉLIORATION DE LA RECONSTITUTION DE LA MOELLE OSSEUSE ET DE LA RÉCUPÉRATION PÉRIPHÉRIQUE DES NUMÉRATIONS DE NEUTROPHILES ET DE PLAQUETTES) is held by AOP ORPHAN PHARMACEUTICALS GMBH [AT]. Status: granted. Granted Aug 21, 2025. Expires Aug 16, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025172541?
AOP ORPHAN PHARMACEUTICALS GMBH [AT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does WO 2025172541 expire?
Our index shows an expiration date of Aug 16, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.